Press Releases Heidelberg Pharma AG Deutsche Boerse AG

Equities

HPHA

DE000A11QVV0

Market Closed - Deutsche Boerse AG Other stock markets 03:16:32 2024-05-17 EDT			5-day change	1st Jan Change
2.95 ^EUR	+0.34%		-0.34%	-19.18%

04-25	Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 29, 2024	CI
04-23	Transcript : Heidelberg Pharma AG - Special Call

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Heidelberg Pharma : Agenda and convening of the general meeting (published in Bundesanzeiger on 13 May 2024)	05-15	PU
Heidelberg Pharma : Report of the Management Board on agenda item 5	05-15	PU
Heidelberg Pharma : Aktuelle Unternehmenspräsentation, Mai 2024	05-14	PU
Heidelberg Pharma : Current Company Presentation, May 2024	05-14	PU
Heidelberg Pharma : Remuneration Report 2023	04-29	PU
Heidelberg Pharma : Remuneration report for the financial year 2022/2023 including audit opinion	04-28	PU
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024	04-25	EQ
DD: Heidelberg Pharma AG: Walter Miller, buy	04-17	EQ
Heidelberg Pharma to host R&D Webinar following novel data presented at AACR	04-05	EQ
PM: Heidelberg Pharma receives Orphan Drug Designation from the FDA for its ATAC candidate HDP-101	03-28	AQ
Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101	03-27	EQ
DD: Heidelberg Pharma AG: Dr. Georg F. Baur, buy	03-26	EQ
Heidelberg Pharma : Presentation Analyst and Press Conference 2024	03-25	PU
Heidelberg Pharma : Präsentation Bilanzpressekonferenz 2024	03-25	PU
Heidelberg Pharma announces financial figures and reports on successful business performance in 2023	03-25	EQ
Heidelberg Pharma : Presentation	03-21	PU
Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty	03-19	EQ
Heidelberg Pharma : Statement on Corporate Governance 2023 as of 19 March 2024	03-18	PU
Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study	03-18	EQ
PM, Heidelberg Pharma Presents Initial Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR 2024 Meeting	03-07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Heidelberg Pharma AG Deutsche Boerse AG

Equities

HPHA

DE000A11QVV0

Press Releases

Filters